In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae

(2010) Wolfgang Haas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones

(2009) Michelle C. Callegan et al.   ADVANCES IN THERAPY

Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study

(2009) Paul Karpecki et al.   CLINICAL THERAPEUTICS

Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis

(2009) Michael E. Tepedino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Ocular Pharmacokinetics of Besifloxacin Following Topical Administration to Rabbits, Monkeys, and Humans

(2009) Joel W. Proksch et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Benzalkonium Chloride Enhances Antibacterial Activity of Gatifloxacin and Reduces its Propensity to Select for Fluoroquinolone-Resistant Strains

(2009) Christine K. Hesje et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS